Clofazimine: Difference between revisions
From IDWiki
(Created page with "== Background == * Antibiotic * Indicated for leprosy and non-tuberculous mycobacteria * Has never been studied in an RCT * Mechanism of action is postulated to be redox cycling and memrane destabilization and dysfunction == Safety == === Adverse Effects === * Skin darkening: exposure-related, onset is gradual. Not permanent, will slowly resolve after stopping the drug. * Dry skin and generalized pruritus * QT prolongation and possibly torsades de pointes...") |
No edit summary |
||
| Line 4: | Line 4: | ||
* Indicated for [[leprosy]] and [[non-tuberculous mycobacteria]] |
* Indicated for [[leprosy]] and [[non-tuberculous mycobacteria]] |
||
* Has never been studied in an RCT |
* Has never been studied in an RCT |
||
| − | * Mechanism of action is postulated to be redox cycling and |
+ | * Mechanism of action is unknown, but postulated to be redox cycling and membrane destabilization and dysfunction |
| + | |||
| + | == Dosing == |
||
| + | |||
| + | * Multibacillary leprosy: 50 mg p.o. once daily (in combination with other medications) |
||
| + | * Erythema nodosum leprosum: 100 mg p.o. 3 times daily for 12 weeks, then twice daily for 12 weeks, then once daily for 12 to 24 weeks (+/- prednisolone) |
||
| + | * Non-tuberculous mycobacteria: 100 to 200 mg p.o. once daily (in combination with other medications) |
||
| + | * Tuberculosis: 100 mg p.o. once daily (in combination with other medications) |
||
== Safety == |
== Safety == |
||
Latest revision as of 09:36, 24 August 2023
Background
- Antibiotic
- Indicated for leprosy and non-tuberculous mycobacteria
- Has never been studied in an RCT
- Mechanism of action is unknown, but postulated to be redox cycling and membrane destabilization and dysfunction
Dosing
- Multibacillary leprosy: 50 mg p.o. once daily (in combination with other medications)
- Erythema nodosum leprosum: 100 mg p.o. 3 times daily for 12 weeks, then twice daily for 12 weeks, then once daily for 12 to 24 weeks (+/- prednisolone)
- Non-tuberculous mycobacteria: 100 to 200 mg p.o. once daily (in combination with other medications)
- Tuberculosis: 100 mg p.o. once daily (in combination with other medications)
Safety
Adverse Effects
- Skin darkening: exposure-related, onset is gradual. Not permanent, will slowly resolve after stopping the drug.
- Dry skin and generalized pruritus
- QT prolongation and possibly torsades de pointes
- Crystal deposition in liver, spleen, and lymph nodes, usually presenting as worsening abdominal pain
